Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Solid Biosciences Inc.

35 indications, side-by-side phase, drug & LoA

$7.14

-0.08 (-1.11%)

C 56Pipeline Score Undervalued Biotech · Clinical
Market Cap
651.74 M
EPS
-1.95
P/E Ratio
-
Value Trade
6.82 M
SEC Financials
Q1 2026

  • Dilution Risk

    15%

  • R&D Expenses

    46.14 M

  • Operating CF

    -47.23 M

  • Total Assets

    422.89 M

  • Total Liabilities

    48.76 M

  • Equity

    374.13 M

  • D/E Ratio

    12,345

-10.9 %
Week
-19.66 %
1 Month
14.53 %
3 Month
47.27 %
6 Month
-88.65 %
5 Year
-98.27 %
All Time
Cash Data
Stable

  • Cash Position

    380.68 M

  • Monthly Burn

    15.74 M

  • Runway

    23.2 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 12, 2026
Overview
Volume
1.66 M
52 Week Range
2.83 - 8.87
% held by Insiders
20.57 %
% held by Institutions
82.88 %
Enterprise Value
291.08 M
Total Shares
98.33 M
Short %
14.38 %
Float Shares
66.77 M
Company Description
HQ: 500 RUTHERFORD AVENUE, CHARLES...
Employees:121
https://www.solidbio.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
phase 1b data readout example
Phase 1b
—
Gene Therapies
Rare Diseases
Phase 1b
—
Gene Therapies
Rare Diseases
Phase 1b
—
Gene Therapies
Rare Diseases
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C56
Pipeline Score
$2.0B
Pipeline Value
Undervalued
Valuation Signal
7
Drugs Scored
3.1x
rNPV / MCap
Top 85%
Micro Cap
(rank 137 of 905)
Percentile Rank
Solid Biosciences Inc. carries a moderate pipeline score (56/100), with $5.0B risk-adjusted pipeline value, led by IP in Small Cell Lung Cancer (Phase 3), across $69B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
IP
Small molecule		Small Cell Lung CancerPhase 3NCT0034949246% $3.1B COMPLETED 372 - -Oct 1, 2013 -Dec 4, 2013
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
SGT-003
Duchenne Muscular Dystrophy
Phase 1/2
2025-08-13
SGT-003
Duchenne Muscular Dystrophy
Phase 1/2
2025-08-13
SGT-003
Duchenne Muscular Dystrophy
Phase 1/2
2025-08-13
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in SLDB
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
SLDB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SLDB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SLDB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
SLDB Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
SLDB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Solid Biosciences Inc. (SLDB) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How SLDB ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Cardiac Arrhythmias #5 of 13 PHASE 1 SGT-501
MDT ·dev ABT ·dev MIST
$29.52B 0.52 CONTENDER
Rare Neurological Disorders #12 of 46 PHASE 3 SGT-003
IONS BIIB SRPT
$139.4B 0.84 CONTENDER